Agios Pharmaceuticals | Beneficio Bruto En Ventas



Gross Profit On Sales Cambio Fecha
AbbVie USD 9.34B 1.36B 2025-03
Agios Pharmaceuticals USD 10.75M 3.11M 2025-06
Alnylam Pharmaceuticals USD 630.74M 107.59M 2025-06
Amgen USD 6.17B 624M 2025-06
Arrowhead Research 542.71M 715.79M 2025-03
Astellas Pharma JPY 410.96B 28.53B 2025-06
AstraZeneca USD 11.98B 637M 2025-06
Bayer EUR 6.38B 1.74B 2025-06
Biogen USD 2.04B 238.8M 2025-06
BioMarin Pharmaceutical USD 670.47M 76.89M 2025-06
Bristol-Myers Squibb USD 8.9B 714M 2025-06
Daiichi Sankyo JPY 382.25B 42.1B 2025-06
Eli Lilly USD 10.5B 624.7M 2025-03
Exelixis USD 548.79M 12.52M 2025-06
Gilead Sciences USD 5.58B 453M 2025-06
GlaxoSmithKline GBP 5.82B 229M 2025-06
Incyte USD 1.14B 151.67M 2025-06
Ionis Pharmaceuticals USD 448M 317.85M 2025-06
Merck USD 12.99B 224M 2025-06
Moderna USD 18M 1000K 2025-06
Novartis USD 11.51B 1.12B 2025-06
Novartis USD 10.24B 313M 2024-12
Pfizer USD 11.12B 987M 2025-03
Regeneron Pharmaceuticals USD 3.15B 581M 2025-06
Roche Holding CHF 11.69B 48M 2024-12
Sarepta Therapeutics USD 457.87M 149.43M 2025-06
Vertex Pharmaceuticals USD 2.56B 150M 2025-06


Agios Pharmaceuticals Beneficio Bruto En Ventas - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.